Director · Avalo Therapeutics, Inc. · Common Stock
Side
SELL
Value
$118K
Shares
8,200
Price
$14.35
Executed
Nov 14, 2025
Disclosed
Nov 17, 2025
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Nov 14 executedNov 17, 2025 disclosed
AVTX · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Goldman Jonathan filed this Form 4 reporting a open-market sale of AVTX on Nov 14, 2025. It became public on Nov 17, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Goldman Jonathancik:0002013869
Issuer
Avalo Therapeutics, Inc.cik:0001534120
Revision history · 0
No field has changed since this record was first ingested.
